BPC-157 + TB-500 Stack: Complete Protocol, Dosing, and Evidence Review

What Are BPC-157 and TB-500?

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. Researchers have studied it in rodent models for gastric ulcer healing, tendon and ligament repair, and neurological protection. TB-500 is a short peptide fragment corresponding to amino acids 17-23 of thymosin beta-4 (TB4), a protein involved in actin sequestration, cell migration, and wound healing.

Neither compound has cleared Phase II clinical trials in humans as of July 2025. The FDA has not approved either peptide for therapeutic use, and the FDA's 503A compounding pharmacies are increasingly restricted from dispensing both compounds following the 2023-2024 guidance updates on bulk peptide compounding.

BPC-157: Core Biology

BPC-157 appears to activate the growth hormone receptor (GHR) independently of growth hormone itself, based on findings published in rodent models [1]. Separate animal work demonstrated that BPC-157 promotes angiogenesis through upregulation of vascular endothelial growth factor (VEGF) and modulation of nitric oxide synthase, which may explain the accelerated wound-closure times observed across multiple rodent injury models [2].

A 2018 rodent study in the Journal of Physiology and Pharmacology found that BPC-157 administered at 10 mcg/kg significantly accelerated Achilles tendon healing compared to saline controls, with improved collagen fiber alignment at 28 days [3]. Extrapolating that rodent dose directly to humans is not scientifically valid without human pharmacokinetic data.

TB-500: Core Biology

Thymosin beta-4 is one of the most abundant intracellular peptides in mammalian tissue. The TB-500 fragment (residues 17-23) retains the actin-binding property of the full molecule. By sequestering G-actin monomers, TB-500 shifts the intracellular actin equilibrium in a way that promotes cell migration into wound sites [4].

A 2010 paper in Annals of the New York Academy of Sciences documented that TB4 promoted cardiac repair in rodent infarct models by activating resident progenitor cells, a finding later extended to skeletal muscle repair models [5]. The anti-inflammatory effects appear to be mediated in part through downregulation of interleukin-1 beta and TNF-alpha.

Can You Stack BPC-157 With TB-500?

Yes, combining BPC-157 and TB-500 is pharmacologically rational based on their distinct receptor targets, though no controlled human data confirm additive or synergistic effects. BPC-157 primarily operates through GHR and nitric oxide pathways, while TB-500 works through actin dynamics and cytokine modulation. Because these mechanisms do not share a major downstream rate-limiting step, stacking them is unlikely to produce receptor competition.

Why Practitioners Combine Them

The theoretical basis for combining these two peptides is that tissue repair involves at least three overlapping processes: angiogenesis, cellular migration, and extracellular matrix remodeling. BPC-157 appears strongest on angiogenesis and collagen production in animal models, while TB-500 appears strongest on cell migration and inflammation control. Addressing multiple phases of repair simultaneously is the core rationale practitioners cite.

The HealthRX clinical team reviewed the preclinical literature and practitioner-reported outcomes from over 200 patient consults to produce the following tiered evidence framework for this stack:

Tier 1 (Animal RCT support): BPC-157 for tendon and gastric mucosal repair; TB4/TB-500 for cardiac and skeletal muscle repair. Tier 2 (Mechanistic plausibility, no animal RCT): Combining both for multi-tissue repair combination. Tier 3 (Practitioner-reported only): Specific dose ratios and injection timing in humans.

All human protocols currently sit at Tier 2 or Tier 3. Patients and clinicians should treat the stack with appropriate skepticism.

What the Animal Data Actually Show About Combination Use

Only a small number of rodent studies have examined BPC-157 and TB4 together. A 2020 rodent study in Current Pharmaceutical Design combined BPC-157 with several other peptides in a traumatic brain injury model and observed improved neurological recovery scores, though TB-500 was not the co-administered peptide in that specific paper [6]. No published peer-reviewed paper as of mid-2025 has directly compared BPC-157 plus TB-500 against either peptide alone in any animal model. That absence is a meaningful evidence gap.

Complete Dosing Protocol for the BPC-157 + TB-500 Stack

The dosing ranges below are derived from rodent dose-extrapolation, allometric scaling, and practitioner-reported outcomes. They are not FDA-validated and should not be interpreted as medical prescriptions.

BPC-157 Dosing

The most commonly reported human dose range is 250-500 mcg per injection. In rodent studies, effective doses cluster around 10 mcg/kg body weight. Applying the standard 12.3x rodent-to-human allometric scaling factor to a 75 kg human yields a rough estimate of approximately 60 mcg. Most practitioners report using doses 4-8x higher than this allometrically scaled figure, which illustrates how speculative the current human dosing field remains [7].

BPC-157 may be administered:

• Subcutaneously (SC), near the site of injury when applicable
• Intramuscularly (IM), into a target muscle
• Orally, in lyophilized form (though bioavailability data for oral BPC-157 in humans are absent)

Twice-daily SC dosing at 250 mcg per injection (500 mcg total daily) is the most commonly reported practitioner protocol for acute injury phases.

TB-500 Dosing

TB-500 is typically cycled in two phases:

Loading phase (weeks 1-4): 4-5 mg per week, split into two injections of 2-2.5 mg each, administered SC or IM. Maintenance phase (weeks 5-8): 2-2.5 mg once weekly.

Some practitioners use a shorter 2-week loading phase of 5 mg/week followed by 2.5 mg/week maintenance for 6 additional weeks. The pharmacokinetic basis for this split is not established in human studies; the loading concept is borrowed from the thymosin beta-4 literature in veterinary medicine, where TB4 is used (off-label) in racehorses [8].

Injection Schedule: A Sample 8-Week Protocol

The table below reflects the most commonly reported practitioner framework. It is not a clinical guideline.

| Week | BPC-157 | TB-500 | |------|---------|--------| | 1-4 | 250-500 mcg SC or IM, twice daily | 2-2.5 mg SC or IM, twice weekly | | 5-8 | 250-500 mcg SC or IM, twice daily | 2-2.5 mg SC or IM, once weekly | | 9+ | 4-week washout before re-starting | 4-week washout before re-starting |

BPC-157 is typically reconstituted in bacteriostatic water at 2 mg/mL, yielding 250 mcg per 0.125 mL draw for a standard U-100 insulin syringe. TB-500 is commonly reconstituted at 2 mg/mL as well.

Injection Site Considerations

BPC-157 is often injected locally, meaning as close to the injured tissue as safely possible, based on the premise that local delivery concentrates the peptide at the repair site. This is mechanistically plausible given that rodent studies administered BPC-157 directly to lesion sites rather than systemically in most protocols [3].

TB-500 is more commonly administered systemically (abdominal SC fat) because its proposed mechanism of mobilizing circulating progenitor cells does not require local tissue contact.

Safety Profile and Known Risks

What the Preclinical Safety Data Show

BPC-157 has not shown overt toxicity in rodent studies across a range of doses. A 2011 rodent study found no significant changes in liver enzymes, renal function markers, or complete blood count in animals administered BPC-157 for 30 days [9]. However, absence of toxicity in rodent acute-dosing models does not establish human safety, particularly for chronic use.

TB-500 (as full-length thymosin beta-4) was studied in a Phase I trial for cardiac repair. The trial (NCT00684541) enrolled 24 patients post-myocardial infarction and found no serious adverse events attributable to TB4 at doses up to 1,260 mg, though the compound in that trial was the full 43-amino-acid protein, not the TB-500 fragment [10].

Specific Risks to Discuss With a Physician

Tumor promotion concern: BPC-157 promotes VEGF and angiogenesis. Any compound that promotes blood vessel growth carries a theoretical concern in individuals with undiagnosed or known malignancy, though no rodent study has demonstrated tumor promotion with BPC-157 specifically [2].

Immune modulation: Thymosin beta-4 is involved in thymic T-cell maturation. Whether the short TB-500 fragment meaningfully alters immune function at the doses used in practitioner protocols is unknown.

Contamination risk: Neither BPC-157 nor TB-500 is manufactured under FDA Good Manufacturing Practice (GMP) standards for human therapeutic use. Research-grade peptides have variable purity. A 2020 analysis published in JAMA found that a substantial portion of compounded and research-chemical products contained incorrect active ingredient concentrations or contaminants [11].

No pharmacovigilance data: Because these compounds are not approved drugs, adverse events are not captured in any systematic pharmacovigilance system. Serious reactions would not be tracked by the FDA MedWatch database under a product-specific code.

Absolute Contraindications (Practitioner Consensus)

Based on mechanistic risk rather than RCT data, the following are commonly cited contraindications by practitioners:

• Active or history of malignancy (VEGF promotion risk)
• Pregnancy or breastfeeding (no reproductive safety data)
• Age <18 years (developing endocrine axis; no pediatric data)
• Concurrent use of anticoagulants without medical supervision

Drug Interactions and Co-Administration Considerations

Stacking With Other Peptides

Some practitioners combine BPC-157, TB-500, and growth hormone secretagogues (such as ipamorelin or CJC-1295) in broader recovery stacks. The mechanistic rationale is that GH secretagogues increase systemic IGF-1, which may amplify the angiogenic and tissue-repair signals from BPC-157 and TB-500.

No published study has examined triple-peptide combinations. The interaction risk is unknown. Adding more compounds increases the likelihood of confounded adverse effects if something goes wrong.

Stacking With NSAIDs

Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit prostaglandin synthesis and may blunt some of the inflammatory signaling that drives the early phases of tissue repair. Concurrent NSAID use could theoretically reduce TB-500 efficacy, since early inflammatory cytokine release is part of the repair cascade that TB-500 modulates rather than suppresses entirely. This is speculative.

Stacking With Corticosteroids

Corticosteroids suppress the immune and inflammatory environment systemically. BPC-157 has demonstrated protective effects against corticosteroid-induced tendon damage in rodent models [12], which is one reason some practitioners add BPC-157 when patients require steroid injections. Whether combining corticosteroids with both peptides alters net outcomes is unknown.

Who Uses This Stack and Why

Athletes and Recreational Fitness

The largest self-reported user group for the BPC-157 plus TB-500 stack is athletes recovering from soft-tissue injuries: rotator cuff strains, Achilles tendinopathy, partial ligament tears, and similar conditions. Forum data from platforms like Reddit (r/Peptides) and professional bodybuilding communities consistently identify this as the most popular peptide pairing, with users citing accelerated return-to-training timelines.

These are anecdotal reports. Confirmation bias is a major concern: people who did not recover are less likely to report their outcomes publicly.

Post-Surgical Recovery

Some surgeons and sports medicine physicians (primarily in countries outside the US where the regulatory environment differs) use BPC-157 and TB-500 as adjuncts to post-surgical rehabilitation. The theoretical basis is that promoting angiogenesis and cellular migration during the remodeling phase of surgical repair may improve tissue quality.

The American Academy of Orthopaedic Surgeons has not issued any guideline supporting peptide use in post-surgical recovery. The absence of a recommendation reflects the absence of human trial data rather than active evidence of futility.

Chronic Tendinopathy

Tendinopathy represents a condition where the standard-of-care interventions (eccentric loading, PRP, corticosteroids) produce inconsistent results. Patients with chronic tendinopathy who have exhausted evidence-based options sometimes seek peptide stacks through compounding pharmacies or research chemical suppliers. A 2023 systematic review in the British Journal of Sports Medicine found that PRP injection for chronic mid-portion Achilles tendinopathy produced only modest improvement over saline at 24 weeks, reflecting the broader difficulty of treating this condition [13]. This context explains, though does not justify, the off-label interest in BPC-157 and TB-500.

Monitoring While on This Stack

Because no approved monitoring protocol exists for either peptide in humans, the HealthRX medical team recommends the following baseline and on-cycle labs based on mechanistic risk profiling:

Before starting:

• Complete metabolic panel (CMP) including hepatic function
• Complete blood count (CBC)
• C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) as inflammation baselines
• Cancer screening appropriate for age and sex per USPSTF guidelines [14]

At 4 weeks:

• Repeat CMP to check hepatic and renal function
• Patient-reported outcome measure for pain and function (e.g., VISA-A for Achilles tendinopathy)

At 8 weeks (end of cycle):

• Repeat CMP and CBC
• Assess whether clinical goal (injury recovery, pain reduction) has been met

The absence of a licensed pharmacovigilance system for these compounds means that any adverse event observed during the cycle should be reported to a physician promptly. The FDA MedWatch program (1-800-FDA-1088) accepts voluntary adverse event reports for dietary supplements and unapproved substances [15].

Regulatory and Legal Status

United States

Neither BPC-157 nor TB-500 is approved by the FDA for human therapeutic use. As of 2024, the FDA's guidance on bulk drug substances for 503A compounding pharmacies has restricted both peptides from the list of permissible compounding ingredients. The FDA's 2023 list of bulk drug substances that may be used by 503A pharmacies does not include BPC-157 or TB-500 [16].

Possession for personal use in the US exists in a legal gray zone. Purchasing as a "research chemical" is technically legal in many jurisdictions, but administering it to another person without a license to practice medicine would constitute unlicensed medical practice.

Outside the United States

Regulatory status varies by country. TB4 and BPC-157 are available by prescription or through research channels in parts of Europe, Australia, and Mexico. WADA (the World Anti-Doping Agency) prohibits thymosin beta-4 and its fragments under Section S2 of the Prohibited List (Peptide Hormones, Growth Factors, Related Substances and Mimetics), effective since 2012. Athletes subject to WADA testing who use TB-500 risk a positive test and competitive ban [17].

BPC-157 is not currently on the WADA Prohibited List, though WADA has flagged it as a monitoring compound.

What to Realistically Expect

Recovery timelines reported anecdotally for this stack range from 3-8 weeks for acute soft-tissue injuries, with most users reporting noticeable improvement by week 2-3. Chronic tendinopathy, by contrast, may require the full 8-week cycle before measurable improvement in function.

The placebo effect in pain and recovery contexts is substantial. A 2021 meta-analysis in JAMA Internal Medicine estimated that open-label placebo effects (where patients know they are receiving an active substance but not a proven therapy) account for 20-30% of reported improvement in pain conditions [18]. Any self-reported outcome for an unblinded, uncontrolled peptide protocol must be interpreted with this in mind.

Neither peptide should be viewed as a replacement for physical therapy, progressive loading, and appropriate rest. The evidence base for structured rehabilitation in tendinopathy, summarized in a 2020 Cochrane review, is substantially stronger than anything available for peptide stacks [19].